Lessons learned: the first consecutive 1000 patients of the CCCMunich LMU Molecular Tumor Board.
Kathrin HeinrichLisa Miller-PhillipsFrank ZiemannKorbinian HasselmannKatharina RühlmannMadeleine FlachDorottya BiroMichael von Bergwelt-BaildonJulian HolchTobias HeroldLouisa von BaumgartenPhilipp A GreifIrmela JeremiasRachel WuerstleinJozefina CasuscelliChristine SpitzwegMax SeidenstickerBernhard RenzStefanie CorradiniPhilipp BaumeisterElisabetta GoniAmanda TufmanAndreas JungJörg KumbrinkThomas KirchnerFrederick KlauschenKlaus H MetzelerVolker HeinemannChristoph Benedikt WestphalenPublished in: Journal of cancer research and clinical oncology (2022)
Based on these retrospective analyses, patients with certain malignancies (breast and biliary tract cancer) tend to be more likely to have actionable variants. The low rate of therapeutic implementation (17% of patients receiving a tumor board recommendation) underscores the importance of meticulous follow-up for these patients and ensuring broad access to innovative therapies for patients receiving molecular tumor profiling.